PSG, a growth equity firm focused on technology-enabled services and middle-market software firms, has made a growth investment in DoseSpot, an SaaS platform enabling clinicians to electronically write and transmit prescriptions to pharmacies.
The investment is expected to accelerate DoseSpot’s ability to increase support for its customers and enable a go-to-market strategy to expand its user base. The firm’s software platform works to streamline the prescription process with modern API and integration platform. DoseSpot is able to integrate new and existing health records, dental practice management systems and digital health platforms.
“With PSG’s support and experience scaling SaaS businesses, I’m confident DoseSpot is on track to advance our mission to help prescribers spend more time with their patients and less time writing prescriptions,” stated Andrew Needleman, founder of DoseSpot. “I’m excited about collaborating with PSG’s team to better support our customers in a time of exceptional growth.”
“In our view, DoseSpot offers critical software to facilitate more efficient and effective connections between participants in the electronic prescription ecosystem, including prescribers, payors, pharmacists, and patients,” added Bill Skarinka, PSG Managing Director. “We are excited to build on DoseSpot’s technology which has drawn and retained marquee customers in the rapidly-growing digital health field.”